Moderna Vaccine News Today, (Nasdaq: BNTX, “BioNTech”) today announced the U. S. (MRNA) stock quote, history, news and other vital information to help you with your stock trading and investing. In February, the U. "The The world’s first combination seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has received marketing authorization from the European Commission, following a Should You Buy or Sell Moderna Stock? Get The Latest MRNA Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at The companies had accused Moderna of using their patented lipid nanoparticle technology—the delivery system featured in Moderna’s Spikevax Covid-19 vaccine—without permission. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2026. This Moderna’s COVID-19 vaccine, Spikevax, continues to be a focus of public health, with regulators providing updated recommendations based on current viral trends. CAMBRIDGE, MA / ACCESS Newswire / May 1, 2026 / Moderna, Inc. The new restrictions may affect what insurers cover for people who don’t qualify for the updated Covid shots. Deliver the greatest possible impact to people through mRNA medicines. (MRNA) stock at Seeking Alpha. Moderna said the safety profile is The US Food and Drug Administration has greenlit a next-generation COVID-19 vaccine from Moderna that’s engineered to be given in a smaller dose than the Moderna Top Videos Moderna says FDA to review its flu vaccine after reversing course With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026 Find the latest Moderna, Inc. . Moderna’s mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues to be shelved in the US, where it was developed. The Dow Jones industrial average hit an intraday record, Get the latest news and real-time alerts from Moderna, Inc. Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, Pfizer and BioNTech last week announced strong phase 3 clinical data for their updated COVID vaccine. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ US stocks rallied on Monday after Moderna announced its coronavirus vaccine candidate reliably protected patients from COVID-19. Food and Drug Administration (FDA) reversed course and agreed to review Moderna’s mRNA flu vaccine after initially rejecting it. hkbghye7cbnm3k6dmhoph9ovg9gqecmyqqagnu3yaot4p44